Bevacizumab in advanced cancer, too much or too little?
Jirillo
A
A
Vascon
F
F
Giacobbo
M
M
D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016527:Drug Costs; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab